La Jolla Pharmaceutical Company/ US5034596040 /
2022-08-19 10:00:00 PM | Chg. - | Volume | Bid1:50:03 AM | Ask1:50:03 AM | High | Low |
---|---|---|---|---|---|---|
6.2200USD | - | 267,682 Turnover: 1.56 mill. |
4.0000Bid Size: - | 6.2500Ask Size: - | 6.2400 | 6.2000 |
GlobeNewswire
2020-08-06
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June ...
GlobeNewswire
2020-07-28
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
GlobeNewswire
2020-07-28
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, ...
GlobeNewswire
2020-06-24
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetrap...
GlobeNewswire
2020-06-24
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
GlobeNewswire
2020-05-04
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 202...
GlobeNewswire
2020-04-13
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program ...
GlobeNewswire
2020-04-07
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Us...
GlobeNewswire
2020-04-06
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Us...
GlobeNewswire
2020-04-03
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Us...
GlobeNewswire
2020-04-02
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Us...
GlobeNewswire
2020-03-13
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use...
GlobeNewswire
2020-03-02
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended De...
GlobeNewswire
2020-01-09
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the T...
GlobeNewswire
2019-11-25
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
GlobeNewswire
2019-11-12
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended Sept...
GlobeNewswire
2019-09-05
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conf...
GlobeNewswire
2019-08-29
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
GlobeNewswire
2019-07-23
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for ...
GlobeNewswire
2019-06-28
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for th...